Skip to content
Menu

CG Oncology, Inc. CGON

Full chart Compare
Set alert

Price alert · CGON

All alert types
81.90 USD +1.90 (+2.38%)

Regular-session close

81.90 0.00 0.00%

After hours · Nov 19, 4:25 PM ET

79.96 Day range 84.22
37.01 52-week range 93.95
YTD
+97.25%
1 year
+92.25%

5D +12.95 (+18.77%)

708090FriMonTueWedThu81.95
Market cap
7.32B
Revenue (ttm)
6.17M
EPS (ttm)
-2.76
Shares out
89.32M
Forward P/E
-27.74
YTD return
+97.25%
1-year return
+92.25%
50-day average
68.51
200-day average
67.10
Enterprise value
6.17B
Volume
2.52M
Avg volume
1.19M
Open
84.03
Previous close
80.00
Day's range
79.96 – 84.22
52-week range
37.01 – 93.95
Beta
0.35
Analysts
Strong Buy
Price target
109.69 (+33.9%)
Earnings date
Feb 26, 2027

Key statistics

Price / sales
1186.38
Price / book
7.38
Revenue growth
-3.70%
Free cash flow
-119.27M
Total cash
984.46M
Total debt
9.24M
Return on equity
-28.29%
Short % of float
10.50%

Fundamental scorecard

5 of 25 checks passed on CGON’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CGON Revenue — quarterly 1.60M
CGON Net income — quarterly -56.89M
CGON EPS — quarterly -0.64

Earnings

CGON recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 26, 2027Dec 30, 2026-0.69———
Nov 6, 2026Sep 30, 2026-0.83411-0.64+0.19+23.27%
Aug 6, 2026Jun 30, 2026-0.66415-0.90-0.24-35.51%
May 8, 2026Mar 31, 2026-0.58-0.71-0.13-22.41%
Feb 27, 2026Dec 31, 2025-0.61-0.51+0.10+16.39%
Nov 14, 2025Sep 30, 2025-0.55902-0.57-0.01-1.96%

Upgrades / downgrades

CGON analyst upgrades and downgrades
DateFirmActionFromTo
Nov 19, 2026GuggenheimmainBuyBuy
Nov 18, 2026Morgan StanleymainOverweightOverweight
Nov 17, 2026JP MorganmainOverweightOverweight
Nov 17, 2026Truist SecuritiesreitBuyBuy
Nov 17, 2026RBC CapitaldownOutperformSector Perform
Nov 17, 2026WedbushmainOutperformOutperform

About CG Oncology, Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on CGON — it syncs with the Stock Master app.

Insider holders

CGON insider holders
InsiderRelationLatest transactionDateShares held
KALOFONOS ISABELOfficerPurchaseNov 17, 20260
KUAN ARTHURChief Executive OfficerPurchaseNov 17, 2026228,916
LIU BRIAN GUAN-CHYUN M.D.DirectorPurchaseJun 24, 20260
MULAY JAMES J.DirectorConversion of Exercise of derivative securityJul 9, 20260
POST LEONARD EDirectorConversion of Exercise of derivative securityNov 15, 20261,000
SONG HONG FANGDirectorSaleSep 2, 20250

Institution ownership

CGON institution ownership
Holder% heldSharesValueReported
RTW Investments LP9.53%8,514,590697.34MSep 29, 2026
T. Rowe Price Investment Management, Inc.7.53%6,726,945550.94MSep 29, 2026
Decheng Capital LLC7.13%6,371,669521.84MSep 29, 2026
Blackrock Inc.7.11%6,347,335519.85MSep 29, 2026
Wellington Management Group, LLP5.51%4,917,082402.71MSep 29, 2026
FMR, LLC5.14%4,594,462376.29MSep 29, 2026

Fund ownership

CGON fund ownership
Holder% heldSharesValueReported
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund3.20%2,860,428234.27MJul 30, 2026
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App2.88%2,574,868210.88MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.67%2,383,134195.18MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.14%1,911,075156.52MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.93%1,720,068140.87MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.73%1,541,674126.26MSep 29, 2026